The International Index is a powerful predictor of outcome in the aggressive non-Hodgkin's lymphomas that is based solely on clinical features. Proliferative activity (% S-phase) measured by flow cytometry has been reported t o have prognostic significance in many series and may represent a biologic correlate of clinical behavior that further defines prognosis. Flow cytometric analysis of cellular DNA content and proliferative activity (' YO S-phase) was performed on fixed paraffin-embedded biopsy specimens from 242 previously untreated patients with diffuse, aggressive nonHodgkin's lymphomas entered on phase 111 intergroup clinical trials. The International Index was calculated for each patient based on stage, lactate dehydrogenase, performance status, number of extranodal sites, and age, as previously reported. The International Index consistently predicted response t o therapy ( P = ,027) and survival (P = .007) in this LTHOUGH THEIR natural history places them among A the most deadly of the non-Hodgkin's lymphomas (NHLs), the diffuse, aggressive NHLs are now known to be highly responsive to combination chemotherapy and to be curable in 30% to 45% of advanced-stage cases.' However, for the individual patient, the prognosis remains somewhat uncertain. For many years, clinical features such as the presence of bone marrow involvement or bulky abdominal disease appeared to provide a crude guide to prognosis.' More recently, an international effort involving individual institutions and cooperative groups in the United States, Canada, and Europe resulted in the International Index, a powerful predictive model based on readily available clinical pretreatment prognostic factors? Easily quantifiable biologic features such as cell proliferative activity may provide additional prognostic information beyond that derived from the clinically based International Index.
A the most deadly of the non-Hodgkin's lymphomas (NHLs), the diffuse, aggressive NHLs are now known to be highly responsive to combination chemotherapy and to be curable in 30% to 45% of advanced-stage cases.' However, for the individual patient, the prognosis remains somewhat uncertain. For many years, clinical features such as the presence of bone marrow involvement or bulky abdominal disease appeared to provide a crude guide to prognosis.' More recently, an international effort involving individual institutions and cooperative groups in the United States, Canada, and Europe resulted in the International Index, a powerful predictive model based on readily available clinical pretreatment prognostic factors? Easily quantifiable biologic features such as cell proliferative activity may provide additional prognostic information beyond that derived from the clinically based International Index.
Biologic correlates of clinical behavior in the diffuse, aggressive lymphomas have been sought for many years. 4 In early studies, flow cytometric analysis was used to assess cell proliferation and to identify the presence of DNA aneuploid stemlines within fresh lymphoma biopsy specimens.' New techniques for extracting nuclei from paraffin-embedded tissue for DNA content analysis6 facilitated study of archival lymphoma specimens at many centers. Early reports that proliferative activity correlated with the categories of the International Working Formulation' classification of lymphoma^',^ led us to first study the clinical and prognostic implications of proliferative activity and DNA aneuploidy using flow cytometry in 50 patients with diffuse large-cell lymphomas." In this relatively small number of heterogeneously treated patients with diffuse large-cell lymphoma, proliferative activity was a significant independent detenninant ( P < ,001) of clinical behavior. To confirm and extend these preliminary findings, a large prospective study of DNA content (E6486) in archival paraffin-embedded clinical biopsy specimens from uniformly staged and treated patients with the diffuse, aggressive lymphomas was initiated through the Eastern Cooperative Oncology Group (ECOG). Clinical features represented by the International Index were series. DNA aneuploidy was shown in 57% of cases, but was not predictive of clinical outcome. The median % S-phase was 9.9 (median coefficient of variation, 3.690), which was highly correlated with mitotic index ( P = .0001). Although a trend associating low proliferative activity with good early survival and very high S-phase with B shortened survival was shown, International Index risk was the only significant predictor of survival in the multivariate analysis. Although proliferative activity quantitated by flow cytometric analysis of nuclei extracted from paraffin-embedded specimens is probably predictive of survival, it is a less powerful prognostic indicator than clinical parameters represented by the International Index and provides no additional prognostic information. 0 1996 by The American Society of Hematology.
then compared with DNA content analysis as indicators of prognosis. Although biologic features may in the future supplant clinical characteristics for determining prognosis, traditional DNA content analysis adds little to the International Index in identifying risk groups.
MATERIALS AND METHODS

Selection of patients.
Patients with stage III or lV diffuse largecell or diffuse mixed-cell NHL (groups F through H in the Working Formulation)' registered for the ECOGs randomized trial of combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or low-dose methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD; E6483), from July 1984 through January 1988, were eligible for this study of ploidy and proliferative activity." In July 1988, the ECOG joined The Southwestem Oncology Group's ongoing phase I11 comparison of CHOP with three newer regimens in the treatment of patients with intermediate-grade or high-grade NHL (groups D through H and group J by the Working Formulation; E3487), and registered ECOG patients were also eligible for this ancillary study of DNA content analysis.'2 These newer combinations included the following: m-BACOD; prednisone, doxorubicin, cyclophosphamide, and etoposide, followed by cytarabine, bleomycin, vincristine, and methotrexate with leucovorin rescue (ProMACE-CytaBOM); and methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B). Eligible patients had bulky stage I1 or stage 111 or IV disease. Criteria for patient enrollment on the ancillary study required that paraffin blocks from the initial diagnostic specimen be available for submission and that the embedded tissue have a minimal transverse diameter of 0.4 cm and sufficient depth to provide a minimum of three 50-pm sections for DNA content study and two routine hematoxylin and eosin sections (5 pm). Material fixed in BS-formalin or Zenker's fixative was not acceptable for technical reasons.
Clinical treatment protocols. The phase 111 clinical trial comparing CHOP and m-BACOD properly enrolled 325 eligible and evaluable patients with Ann Arbor stage 111 or 1V disease with normal renal, pulmonary, and hepatic function. Eighty-nine percent of the cases underwent a secondary central pathology review. Patients were uniformly staged with bone marrow trephine biopsies and computed tomography. Eight 2 1 -day cycles of chemotherapy were administered as previously described. There were no significant differences in the complete remission rates, time to treatment failure, diseasefree survival, or overall survival between the treatment arms.
Similarly, the clinical trial comparing CHOP, m-BACOD, Pro-MACE-CytaBOM, and MACOP-B enrolled 899 previously untreated eligible patients. All cases underwent central pathology review. The different chemotherapy regimens were administered as previously described in the original reports of the regimens. Rates of complete and partial remission, disease-free survival, and overall survival were similar among the four treatment groups.
Five-micron sections for routine staining with hematoxylin and eosin were obtained from each biopsy to show the presence of malignant lymphoma within the material to be studied. The portion of the biopsy specimen containing predominantly lymphoma was marked and the connective tissue and/or necrotic areas were excised from the paraffin block. After cutting three 50-pm sections for DNA content analysis, a second adjacent 5-pm section was stained and examined to verify that lymphoma was present throughout the specimen under study. These sections were all reviewed by the study hematopathologist (D.V.) and the presence of necrosis and sclerosis was noted. A mitotic index was assigned to each case accrued from the ECOG trial comparing CHOP and m-BACOD by counting the number of mitoses per 10 high-powered microscopic fields and calculating an average.
Paraffin-embedded tissue was deparaffinized and dissociated using a previously reported modification of the method described by Hedley et a1.h.'" After dissociation, nuclei were permeabilized with Triton X (0.1%), incubated with RNAase A, and stained with propidium iodide (SO pg/mL) as detailed previously."' Cellular DNA content and proliferative activity were quantitated using a Coulter Epics 752 flow cytometer (Coulter, Miami, FL). Fluorescent microspheres were used to assess instrument performance at the beginning of each run and as an external fluorescence standard. Seven control specimens containing follicular hyperplasia had been shown to be entirely diploid when analyzed for DNA content in our laboratory previously.'" In addition, DNA content analysis of matched single-cell suspensions and paraffin-embedded material had been previously performed and reported and showed close agreement in proliferative activity."' Cellular aggregates were routinely assessed microscopically and in all cases constituted less than 10% of events. Pulse processing (peak v integral fluorescence bitmap) was used to minimize inclusion of residual cell aggregates within the DNA histogram.
Deparafinization, dissociation, and stuining.
Cell cvde and DNA aneuploidy una1ysi.s. DNA content analysis of flow cytometry data for these cases was performed using the Multicycle Software (Phoenix Flow Systems, San Diego, CA) to analyze DNA ploidy and to calculate the S-phase fraction after the subtraction of debris using a sliced nuclei algorithm, as detailed previously.'' To ensure comparability between the measurements of proliferative activity in the DNA diploid and the DNA aneuploid cases, cell cycle analysis for determination of the S-phase fraction was based on the average S-phase. Thus, for DNA aneuploid cases, this measurement was based on the weighted average of S-phase fraction of the DNA diploid and DNA aneuploid cellular subpopulations. Whereas the % S calculated for the aneuploid cell subpopulation will more accurately reflect the proliferative activity of the neoplastic cells than the weighted average, this measurement was also obtained. An aneuploid stemline was considered present only if two distinct GJG, populations were evident. The DNA index was calculated by dividing the mean fluorescence channel number of the higher (aneuploid) peak by the mean channel number of the lower (DNA diploid) peak. Only specimens with a single GJG, peak and a coefficient of variation (CV) of 5.0% or less were considered to be DNA diploid. Those with higher CVs were considered to be inevaluable for DNA ploidy. Parallel staining and analysis of fresh peripheral blood leukocyte samples consistently showed CV values of less than 1.5%.
The International Index was calculated for each patient based on stage, lactate dehydrogenase (LDH), performance status, number of extranodal sites, and age, as previously reported.'
Statistical methods. Univariate associations between dichotomous variables were evaluated with Fisher's Exact test. Associations involving ordered categorical variables were evaluated with a Wilcoxon Rank Sum test.I4 Analyses of the joint association of multiple variables with response were evaluated with logistic regression. Univariate and multivariate analyses of disease-free survival and survival were evaluated with proportional hazards regression. Survival distributions were produced using the method of Kaplan and Meier. The percentage of cells in S-phase was considered both as a continuous variable and when dichotomized. The cutpoint for the analysis of the association with response was evaluated with Classification and Regression Trees (CART)," and the cutpoint for the association of S-phase with survival was evaluated with Martingale residuals.''
RESULTS
Internutionul index.
Patient selection. Of the 227 eligible ECOG cases properly enrolled on the randomized clinical trial CHOP versus m-BACOD (E6483), 201 were also entered on the ancillary study of DNA content (E6486). Thirty-six of these cases were excluded from the final analysis of the clinical trial; thus, 165 or 73% of the eligible and evaluable ECOG cases were enrolled on the flow cytometric study. Of the 165 entries, adequate and appropriate material was received in 143 cases. Only 3 cases proved unanalyzable by flow cytometry.
Of the 285 eligible and analyzable ECOG cases enrolled on the four-arm SWOG comparison of CHOP, m-BACOD, Pro-MACE CytaBOM, and MACOP-B (E3487), adequate material was received on 114 registered cases. Twelve cases were unanalyzable for ploidy and S-phase.
To determine if a representative subset of cases from the two clinical trials had been analyzed by flow cytometry, the on-study characteristics of the patients entered on this study of ploidy and proliferative activity (Table 1) were compared with the pretreatment variables for ECOG patients entered on E6483 and E3487. There was no difference in the distri- bution of cases by stage between the clinical trials and the ancillary study of DNA content. With respect to International Index risk groups, the low-risk and high-intermediate-risk groups were slightly overrepresented and the low-intermediate and high-risk groups were underrepresented in the laboratory study. Whereas 18% and 33% of all cases from the clinical trial were from the low-risk and high-intermediaterisk groups, respectively, 20% and 36% of the cases studied by flow cytomew were of these categories. Similarly, 35% and 14% of the patients entered on the clinical trials were low-intermediate-risk and high-risk, respectively, and 32% and 1 1 % of the cases studied for DNA content were of these risk groups. The complete remission (CR) rates of patients whose pathologic specimens had been studied (54% on E6483 and 46% on E3487) were consistent with the overall CR rates seen on the studies (53% and 50%, respectively).
For each sample, the mean 2 SE number of nuclei counted was 39,082 ? 1,530. The presence of a DNA aneuploid peak may be obscured in cases in which the CV exceeds 5%; therefore, DNA ploidy could not be reliably assessed in 15 cases. The median CVs for the diploid and aneuploid cases, respectively, were 3.6% (range, 2.0% to 5.0%) and 3.5% (range, 1.8% to 11.2%). In 11 cases, proliferative activity was indeterminate because of excessive debris.17
Flow cytometric analysis.
The results of the flow cytometric analysis of DNA content are summarized in Table 2 . The median % S-phase overall was 9.9%. Overall, 57% of the cases were DNA aneuploid. The median DNA index was 1.2 (range, 0.8 to
2.3).
Among aneuploid cases for which it was technically possible to calculate the % S for the aneuploid subpopulation of cells (n = log), the median % S for the aneuploid cells was 16.7 (range, 0.3 to 67.7).
In the 143 cases from E6483, the mitotic index and % Sphase were highly correlated as continuous variables (P = .Owl), leading us to discontinue counting mitotic indices on the cases accrued from E3487.
Parameters associated with response. One hundred twenty-three of the patients in this data set achieved CR. Association of the various clinical on-study characteristics with response was investigated ( Table 3 ). The level of LDH and the number of extranodal sites were predictive of response (P = .03 and P = .001, respectively, by Fisher's exact two-tailed test), as was the International Index (P = .027 by Wilcoxon rank test for ordered categories). The Intemational Index was a consistent predictor of complete remission, with 63% of low-risk, 49% of low-intermediate- Neither pathologic classification by the Working Formulation' (diffuse, mixed v diffuse, large-cell) nor the presence of sclerosis or necrosis was predictive of a CR.
When proliferative activity was investigated as a continuous variable by logistic regression analysis, it was not predictive of response. This was true whether the analysis was run with % S-phase in its raw state or when run as its logarithm to normalize the distribution. Using CART" to identify the best cutpoint for dichotomizing this continuous variable, a value of 15.4% was selected for purposes of analysis. Fifty-five percent of patients with proliferative activity below the cut-point entered CR, whereas only 38% of those with % S-phase above this value did ( P = .022). However, rounding the cutpoint up to 16% or down to 15% completely eliminated the significance, suggesting that % Sphase is probably not strongly associated with response. In a logistic regression analysis including DNA aneuploidy, sclerosis, clinical trial (E6483 v 3487), % S-phase (as a continuous and dichotomous variable and its log), necrosis, and International Index risk category, only the risk group was significantly associated with CR ( P = .025).
Predictors of survival.
Associations between clinical features and DNA content parameters and disease-free survival, time to treatment failure, and survival were investigated. No variable was predictive of disease-free survival or time to treatment failure.
In the survival analysis, elevated LDH levels, International Index risk category (Fig l) , the presence of necrosis, and increasing % S were all associated with poor survival ( P < .05; Table 4 ). However, proliferative activity was no longer a significant prognostic indicator if log % S-phase was substituted, suggesting that a small number of outlier values may be skewing the results. To further evaluate the predictive value of proliferative activity, a Martingale residual analysis was performed.16 Although % S-phase was not significantly associated with survival in this model, a trend associating low proliferative activity (<7% S-phase; n = 77) with good early survival and % S-phase greater than 20% (n = 30) with a shortened time of survival was shown (Fig 1 j. It is possible that this underlies the apparent association ( P = .0208) of S-phase as a continuous variable with survival. However, the association was not consistent between 7% and 20% S-phase or for long-term survival, and it cannot be concluded that % S-phase is an independent predictor of survival.
There was no association between survival and o/c S calculated for the aneuploid subpopulation of cells (9% S,,,) among aneuploid cases for which these data were available. This was true whether % S,, was investigated as a continuous variable ( P = SI) or using the 7% and 20% cut-offs derived in the larger analysis ( P = .80). Index risk category was the only significant predictor of survival in the multivariate analysis. Proliferative activity added no additional prognostic information once cases had been grouped by International Index.
For the smaller sample of cases for which % S was calculated for the aneuploid cell subpopulation, International Index risk category was predictive of survival (low/low-intermediate 1' high-intermediatehigh, P = .012), and this remained true in the joint analysis ( P = ,013).
DISCUSSION
Identification of prognostic features in the diffuse, aggressive NHLs has assumed greater significance now that phase 111 clinical trials comparing conventional CHOP chemotherapy with the newest generation of regimens have shown no benefit to the more intensive and toxic treatments.' ' . I 2 Because less than half of all advanced-stage patients remain disease-free long-term after CHOP chemotherapy, criteria identifying those at high risk of treatment failure should be established so that these patients may be offered alternative investigational therapies. For many years, clinical features such as performance status and level of LDH have been recognized as powerful predictors of outcome in the diffuse, large-cell lymphomas, and their usefulness has been validated once more in the recently reported prognostic factor model. the International Index.*S3 Independent biologically based prognostic indicators in the diffuse, aggressive NHLs have yet to be identified. Although proliferative activity (% S-phase) has been reported to predict outcome in many small Years Years studies, its determination by flow cytometry provided no additional prognostic information to the clinically based International Index in the largest reported series of uniformly staged and treated patients with diffuse, aggressive NHLs. In the search for biologic correlates of clinical behavior, flow cytometric analysis of DNA content has emerged as a powerful guide to prognosis in many malignant diseases. In the NHLs, proliferative activity measured by flow cytometry was found to correlate with the morphologically based low-grade, intermediate-grade, and high-grade categories established by the Working Form~lation.~.~ Similarly, the incidence of DNA aneuploidy was found to correlate with grade by the Working Formulation. Whereas the individual morphologic categories are themselves heterogeneous, DNA content analysis was performed on groups of histologically similar cases in hopes of distinguishing those at high risk of treatment Ploidy was not a consistent indicator of prognosis in most previous s e r i e~.~~.~~ The majority of these studies show proliferative activity, or % S-phase, to have prognostic v a l~e ,~~, *~ although they are predominantly small series of heterogeneously treated patients evaluated retrospectively. Multivariate analysis including clinical features such as the level of LDH or performance status was not always performed, given the relatively small numbers. Like many of the early small series, our initial study of 50 diffuse large-cell lymphoma biopsy specimens showed a striking difference in survival when proliferative activity was studied as a dichotomous variable." In an attempt to confirm these findings and those of others, biopsy specimens from a large number of uniformly staged and treated patients were analyzed in the same laboratory in this study. Whereas none of the three third-generation chemotherapy regimens proved more effective than CHOP, patients enrolled on the ECOG trial of CHOP versus m-BACOD were combined with those entered on the four-arm trial comparing CHOP, m-BACOD, ProMACE-CytaBOM, and MACOP-B."," In this relatively large number of cases, clinical measures of prognosis reflected in the International Index were better predictors of survival than proliferative activity measured by % S-phase. Furthermore, flow cytometric quantitation of % S-phase added no additional prognostic information beyond that of the clinically based International Index. Although proliferative activity was not the best predictor of outcome in this series, it is probably associated with poor survival (along with LDH and the high-intermediate-risk or high-risk categories of the International Index). A small number of outlier values may underlie this result. Nevertheless, a trend associating low proliferative activity with early survival and high proliferative activity with shortened survival was shown. That % S-phase is predictive of survival is also suggested by studies using thymidine labeling or the Ki-67 nuclear proliferation antigen as measures of cell proliferation.z6-2x
When studied as a continuous variable, neither % S-phase nor its logarithm was predictive of response to chemotherapy. As a dichotomous variable, % S-phase was associated with a CR only if the cutpoint was defined as 15.4%. Rounding up or down eliminated the significance. Whereas this association is not robust to small perturbations, proliferative activity is probably not strongly associated with response. This study also underscores the importance of large series of uniformly staged and treated patients, especially in disease entities in which there is substantial heterogeneity. Before any clinical or biologic feature is accepted as a guide to outcome, its predictive value should be validated in a large study. The results of such an analysis are then relevant only to the population of patients studied, ie, in this case, patients with advanced disease treated with combination chemotherapy including an anthracycline. Data on over two thousand patients were compiled for purposes of establishing the International Index. Even the relatively large number of patients enrolled in this study of DNA content became insufficient when subset analysis of complete responders was required.
Use of archival paraffin-embedded specimens rather than fresh unfixed tissue provided for participation from a large number of ECOG member institutions incIuding both academic and community centers, but introduced limitations to the methodology that must be considered in the interpretation of the results. Whereas NHLs generally contain an admixture of neoplastic and benign lymphocytes, S-phase quantitation performed using extracted nuclei may be an inaccurate measure of proliferative activity in the malignant cell population, particularly in diploid cases. In aneuploid tumors, proliferative activity of the malignant cell population uncontaminated by normal lymphocytes may be measured by selecting the aneuploid population. To ensure comparability in the measurements of S-phase in diploid and aneuploid specimens, an average S-phase of all cells was calculated in the aneuploid cases in our analysis. The 9% S for the aneuploid cell subpopulation (% Sa") was also calculated and a separate analysis investigating an association between % S,,, and survival was performed using the smaller sample of only aneuploid cases. If instead of archival paraffin-embedded specimens, fresh, unfixed tissue had been available, multiparameter analysis could have been performed in which staining for DNA and a surface or cytoplasmic antigen specific for-the particular lymphoma (eg, light chain) are performed simultaneously. This provides for a more accurate measure of proliferative activity in the malignant cells in both diploid and aneuploid cases. Future prospective studies should use fresh, unfixed material and multiparameter analysis to insure an optimal measure of S-phase. Proliferative activity may prove to be a superior guide to prognosis than the International Index when measured in this fashion.
Clinical markers of prognosis are, in part, surrogates for biologic characteristics. LDH, for example, is likely to represent, at least in part, cell turnover or proliferative activity. Other methods for measuring this biologic feature include thymidine labeling, staining with Ki-67, and counting mitoses-which was closely correlated with proliferative activity in this study ( P = .0001). It is of interest that a previous study of mitotic indices in NHLs did not show an association with prognosis." LDH may represent tumor burden in addition to the proliferative activity of the neoplasm and therefore be a better overall predictor of response than either of these two parameters. Although flow cytometric analysis of DNA content using paraffin-embedded specimens proved to be a less powerful guide to prognosis than clinical features, there are many new molecular and cellular parameters that may better reflect the biologic character of the disease. Carefully performed prospective studies of large numbers of uniformly treated patients will be required to assess the relative power of these measures. 
